PEN Q2 2023 Earnings — Penumbra, Inc. Revenue & Financial Results | Market Cap Arena

PENPenumbra, Inc.

$13B

Q2 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$261M+25.5% YoY

Gross Profit

$167M63.8% margin

Operating Income

$18M6.8% margin

Net Income

$19M7.3% margin

EPS (Diluted)

$0.48

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$13M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$366M

Stockholders' Equity

$1.1B

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$261M	$208M	+25.5%
Gross Profit	$167M	$134M	+24.5%
Operating Income	$18M	-$139,000	+12969.8%
Net Income	$19M	-$4M	+614.2%

Revenue Segments

Peripheral Vascular

$153M58%

Neuro

$109M42%

Geographic Segments

UNITED STATES

$187M71%

Other Non-US

$75M29%